Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].

Rocconi, Rodney P; Monk, Bradley J; Walter, Adam; Herzog, Thomas J; Galanis, Evanthia; Manning, Luisa; Bognar, Ernest; Wallraven, Gladice; Stanbery, Laura; Aaron, Phylicia; Senzer, Neil; Coleman, Robert L; Nemunaitis, John

Rocconi, Rodney P; Monk, Bradley J; Walter, Adam; Herzog, Thomas J; Galanis, Evanthia; Manning, Luisa; Bognar, Ernest; Wallraven, Gladice; Stanbery, Laura; Aaron, Phylicia; Senzer, Neil; Coleman, Robert L; Nemunaitis, John.

Afiliação

Rocconi RP; University of South Alabama - Mitchell Cancer Institute, Mobile, AL, United States of America.
Monk BJ; Arizona Oncology, Phoenix, AZ, United States of America.
Walter A; ProMedica, Toledo, OH, United States of America.
Herzog TJ; University of Cincinnati Cancer Center, Cincinnati, OH, United States of America.
Galanis E; Mayo Clinic, Rochester, MN, United States of America.
Manning L; Gradalis, Inc., Carrollton, TX, United States of America.
Bognar E; Gradalis, Inc., Carrollton, TX, United States of America.
Wallraven G; Gradalis, Inc., Carrollton, TX, United States of America.
Stanbery L; Gradalis, Inc., Carrollton, TX, United States of America.
Aaron P; Gradalis, Inc., Carrollton, TX, United States of America.
Senzer N; Gradalis, Inc., Carrollton, TX, United States of America.
Coleman RL; US Oncology Research, The Woodlands, TX, United States of America.
Nemunaitis J; Gradalis, Inc., Carrollton, TX, United States of America. Electronic address: Johnnemunaitis@gmail.com.

Gynecol Oncol ; 169: 173, 2023 Feb.

Article em En | MEDLINE | ID: mdl-36456375

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos